Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics and certain senior executives for potential violations of federal securities laws, with a legal deadline for investors to act by December 15, 2025 [2][4]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [5]. - The company conducted Phase 3 VELA trials for sonelokimab (SLK), aimed at treating moderate to severe hidradenitis suppurativa [5]. Allegations and Clinical Data - The lawsuit alleges that MoonLake misrepresented its clinical data and the advantages of SLK's Nanobody structure compared to traditional monoclonal antibody treatments, which may have misled investors regarding the drug's regulatory approval and commercial viability [6][7]. Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [8].

Core Viewpoint - The lawsuit against Avantor, Inc. alleges that the company made materially false and misleading statements regarding its business operations and competitive positioning, leading to significant financial losses for investors during the specified class period [3]. Summary by Sections Lawsuit Details - The class action lawsuit is on behalf of investors who purchased Avantor securities from March 5, 2024, to October 28, 2025, alleging that the company misrepresented its competitive position and failed to disclose adverse effects from increased competition [3]. Financial Performance - On April 25, 2025, Avantor reported weak first quarter results, cutting its 2025 guidance and announcing the resignation of its CEO, resulting in a share price drop of $2.57, or approximately 16.5%, from $15.50 to $12.93 [4]. - On August 1, 2025, the company reported disappointing second quarter results with a year-over-year decrease in net sales and further reduced guidance, leading to a share price decline of $2.08, or approximately 15.48%, from $13.44 to $11.36 [5]. - On October 29, 2025, Avantor disclosed weak third quarter results, including a -5% organic revenue growth and a net loss of $712 million due to a non-cash goodwill impairment charge of $785 million, causing shares to drop by $3.50, or approximately 23.2%, from $15.08 to $11.58 [6].

Core Viewpoint - A class action securities lawsuit has been filed against Blue Owl Capital Inc. for alleged securities fraud affecting investors between February 6, 2025, and November 16, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Blue Owl Capital Inc. faced significant pressure on its asset base due to redemptions from business development companies, leading to undisclosed liquidity issues [2]. - It is alleged that the company was likely to limit or halt redemptions of certain business development companies, which misled investors regarding the company's business, operations, and prospects [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until February 2, 2026, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years by ISS Securities Class Action Services [4].

NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in StubHub Holdings, Inc. ("StubHub Holdings, Inc." or the "Company") (NYSE: STUB) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of StubHub Holdings, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons and entities that purchased or otherwise acquired StubHub common stock pursuant and/or traceable to the registra ...

Core Viewpoint - A class action securities lawsuit has been filed against DeFi Technologies, alleging securities fraud that affected investors between May 12, 2025, and November 14, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that DeFi Technologies faced delays in executing its DeFi arbitrage strategy, which was a key revenue driver for the company [2]. - It is alleged that DeFi Technologies understated the competition from other digital asset treasury companies, impacting its ability to execute its DeFi arbitrage strategy [2]. - The complaint suggests that due to these issues, the company was unlikely to meet its previously issued revenue guidance for the fiscal year 2025 [2]. - Defendants are accused of downplaying the negative impact of these issues on DeFi Technologies' business and financial results, leading to materially false and misleading public statements [2]. Group 2: Legal Process and Participation - Investors who suffered losses in DeFi Technologies during the relevant timeframe have until January 30, 2026, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the United States [4].

NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Telix Pharmaceuticals Ltd. investors who were adversely affected by alleged securities fraud between February 21, 2025 and August 28, 2025. Follow the link below to get more information and be contacted by a member of our team: ht ...

NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Perrigo Company plc ("Perrigo Company plc" or the "Company") (NYSE: PRGO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Perrigo Company plc investors who were adversely affected by alleged securities fraud between February 27, 2023 and November 4, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1 ...

NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in James Hardie Industries plc. ("James Hardie Industries plc." or the "Company") (NYSE: JHX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of James Hardie Industries plc. investors who were adversely affected by alleged securities fraud between May 20, 2025 and August 18, 2025. Follow the link below to get more information and be contacted by a member of our team: htt ...

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud affecting investors between February 23, 2022, and July 30, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Baxter's product, the Novum LVP, had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [2] - It is alleged that Baxter was aware of multiple device malfunctions, injuries, and deaths related to these defects [2] - Baxter's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [2] - The lawsuit suggests that there was an increased risk of customers being instructed to take Novum LVPs out of service and that Baxter would halt all new sales of these pumps [2] - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [2] Group 2: Next Steps for Investors - Investors who suffered losses in Baxter International, Inc. during the specified timeframe have until December 15, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Stride, Inc. ("Stride" or the "Company") (NYSE: LRN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Stride investors who were adversely affected by alleged securities fraud between October 22, 2024 and October 28, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/stride-inc-lawsuit-submission-form ...